About Divi's Laboratories Ltd

Divi’s Laboratories Limited is an Indian multinational pharmaceutical company based in Hyderabad, Telangana, India. Founded in 1990, the company is engaged in the manufacture of generic Active Pharmaceutical Ingredients (APIs), contract research (custom synthesis) of APIs for other pharma companies, specialty chemicals and nutraceuticals. The company operates predominantly in the exports market selling to regulated markets in USA and Europe, as well as locally (India).

 

The company’s product portfolio comprises 2 broad segments:

  • Generic APIs and Nutraceuticals
  • Custom Synthesis of APIs, intermediates and specialty ingredients for other companies

 

In the fiscal year 2014-2015, the company’s exports constituted 87% of gross sales – mainly to advanced markets such as Europe and America.

 

As of 31st March 2015, the company had:

  • 4 manufacturing units in India (with 32 production blocks)
  • 4 R&D Centres in India (with 300+ scientists)
  • 2 subsidiaries in USA and Switzerland

 

The company is listed on the National Stock Exchange (NSE), Bombay Stock Exchange (BSE), as well as Kolkata, Chennai, Delhi and Kochi stock exchanges.

 

Divi's Laboratories Limited at-a-glance

  • Employees ~10,000
  • Manufacturing Facilities 4
  • R&D Centres 4
  • Products 150
  • Patents Filed 11
  • USDMFs Filed 39

 

*Source: http://www.divislabs.com/, http://www.divislabs.com/Chairman%20Speech%202015.pdf

Certifications ISO 9001

ISO 14001:2004

ISO14001:1996

ISO 9002

OHSAS 18001

FSS 22000:2010

 

 

 

History of Divi’s Laboratories Ltd.

Divi’s Laboratories Limited was established in 1990 primarily as an R&D and consultancy company for developing commercial processes for active pharma ingredients (APIs) and intermediates. Within a short span of time, the company expanded its operations successfully to provide turnkey solutions to the domestic pharmaceutical industry.

 

In 1995, Divi’s Laboratories established its first manufacturing facility (Unit-I) on a 500-acre site at Hyderabad, comprising 13 multi-purpose production blocks – and additional space for growth and expansion.

In 2002, the company set up its second manufacturing facility on a 350-acre site at Visakhapatnam (Unit-II), comprising 14 multi-purpose production blocks.

As of 31st March 2015, the company’s operations included:

 

  • 4 multipurpose manufacturing units
      • A 500-acre site in Hyderabad (1995), comprising 13 multi-purpose production blocks for APIs under full cGMP as per US-FDA guidelines
      • A 100-acre export oriented unit (2003), near the port city of Visakhapatnam, comprising 8 production blocks
      • A 260-acre SEZ unit in Bheemunipatnam Mandal in Visakhapatnam district (2006), comprising 5 production blocks
      • Another SEZ unit in Bheemunipatnam Mandal, Visakhapatnam Dist., comprising 5 production blocks
    • 4 R&D Centres (Hyderabad, Choutuppal, Vizag and Chippada)
    • 2 subsidiaries (USA and Switzerland)

Divi’s Laboratories Limited operates from its headquarters and registered office in Hyderabad, Telengana, India.

 

Milestones

  • 1990 – Establishes the Divi’s Research Center (DRC)
  • 1991-3 – Develops several commercial processes for intermediates and bulk actives,

and starts supplying to manufacturing majors

  • 1994 – Changes its name to Divi’s Laboratories Limited to reflect its plans to enter the

manufacturing sector

  • 1995 – Sets up first manufacturing facility at Choutuppal near Hyderabad
  • 1997 – Certified ISO-9002 compliant by SGS-Yarsley (UK)
  • 1999 – Receives Certificate of Suitability (CoS) from European Directorate for Naproxen
  • 2000
    • Receives ISO 9001 Certification from SGS-Yarsley of UK
    • Receives ISO-14001 Certification for efficient Environment Management Systems from SGS International AG of Switzerland
  • 2001 – Receives OHSAS-18001 Certification from BVQI of London
  • 2002 – Starts setting up its second manufacturing facility at Chippada near Visakhapatnam
  • 2003 – Opens a new research center, DRC-Vizag, for research in niche segments
  • 2003 – Launches initial public offering (IPO) and gets listed on Bombay, National and

Hyderabad stock exchanges (i.e. BSE, NSE and HSE)

  • 2004 – US-FDA inspects the Choutuppal unit for the second time
  • 2006 – US-FDA inspects the Visakhapatnam unit for the first time
  • 2008 – US-FDA inspects the Choutuppal for the third time
  • 2008 – KFDA inspects the Visakhapatnam for the first time
  • 2009 – KFDA inspects the Visakhapatnam for the second time
  • 2009 – US-FDA inspects the Visakhapatnam(Unit-2) for the second time.
  • 2011 – German Health Authorities (BGV-Hamburg, EU GMP) inspect the Choutuppal unit
  • 2011 – Japan’s PMDA inspects the Choutuppal unit
  • 2011 – US-FDA inspects the Choutuppal unit for the fourth time
  • 2011 – C-PTAT (US Border Security Force) inspects the Visakhapatnam unit
  • 2012 – Australia’s TGA inspects the Visakhapatnam unit
  • 2012 – US FDA (Dietary Supplement Ingredient) inspects the Visakhapatnam unit
  • 2013 – Slovenian Medicines Agency inspects the Visakhapatnam unit
  • 2014 – KFDA inspects the Visakhapatnam unit for the third time
  • 2014 – US FDA inspects the Visakhapatnam unit for the fourth time
  • 2014 – Mexico’s COFEPRIS inspects the Visakhapatnam unit for the first time
  • 2014 – Mexico’s COFEPRIS inspects the Choutuppal unit for the first time

 

BOARD OF DIRECTORS

  • Chairman & Managing Director: Dr. Murali K Divi
  • Executive Director: Mr. NV Ramana
  • Director, Projects: Mr. Madhusudana Rao Divi
  • Director & President – Operations Mr. Kiran S Divi
  • Independent Directors Dr. G Suresh Kumar,  Mr. R Ranga Rao,  Mr. KVK Seshavataram,  Mrs. S Sridevi

 

Divi’s Laboratories Ltd. Contact Details

REGISTERED OFFICE

Divi’s Laboratories Limited

7-1-77/E/1/303, Divi Towers

Dharam Karan Road

Ameerpet

Hyderabad – 500016

Telangana, India

 

Tel: +91 (40) 2378 6300

Fax: +91 (40) 2378 6460

E-mail: mail@divislaboratories.com
 

Website: http://www.divislabs.com/

 

USA OFFICE

Divi’s Laboratories (USA) Inc

325 Columbia Turnpike

Suite 305

Florham Park, NJ 07932

USA

 

 

Tel: +1 (973) 993 1060

Fax: +1 (973) 993 1070

Email: usmail@divislaboratories.com

 

SWITZERLAND OFFICE

Divi's Laboratories Europe AG

Solothurnerstrasse 15

4053 Basel

 

Tel: +41 61 361 67 53

Fax: +41 61 361 67 55

Email: eumail@divislaboratories.com

 

US GENERICS

Mr. Kiran S Divi

Director & President – Operations

 

 

Email: Kiran@divislaboratories.com

ADMINISTRATION

Mr. K Subba Rao

DGM P & A

Email: ksr@divislaboratories.com

BUSINESS SEGMENTS

Mr. NV Ramana

Executive Director

 

Tel: +91 (40) 2378 6402

Fax: +91 (40) 2378 6493

Email: marketing@divislaboratories.com

INVESTORS

Mr. L Kishore Babu

CFO

 

Email: kishore@divislaboratories.com

 

COMMENTS & SUGGESTIONS

 

Email: http://www.divislabs.com/inside/suggestions.asp

 

Comment!
 
 






* Indicates mandatory field.
Please wait while comments are being sent...